The mutation studies demonstrated that the prosequence of ROL seems to facilitate the folding by providing an intramolecular thiol-disulfide reagent, and proROL is also significantly more stable against thermal inactivation than mROL [ 25, 26].
A large-scale somatic mutation study demonstrated that in approximately 450 tumors, comprising breast, lung, ovarian, pancreatic, and prostate cancer, the SPOP gene was highly mutated in prostate cancer (Kan et al., 2010).
The reduced dox-responsiveness of the F86Y and G138D mutated tTAs is in agreement with previous TetR-mutation studies demonstrating that amino acid substitutions at positions 86 and 138 can cause an induction-deficient phenotype [ 30].
Moreover, direct measures of the impact of synonymous mutations from nucleotide replacement studies demonstrate that they can impact gene expression2,3, presumably through changes to the rate or accuracy of transcription and/or translation4, mRNA stability and folding5, protein secondary structure6,7 and even fitness3,8,9,10,11.
Thus, our studies demonstrate AP2σ2 mutations to result in a more severe FHH phenotype with genotype phenotype correlations, and a dominant-negative mechanism of action with mutational bias at the Arg15 residue.
Intrinsic and ANS fluorescence studies demonstrate that D476N mutation is brought about by structural changes without significant effect on thermostability and flexibility.
In this context, it is worth mentioning that recent studies demonstrate that point mutations located at these ankyrin repeats at the N-terminus either increase or decrease the TRPV4 activity and results in genetic disorders [71] [73].
Thus, some studies demonstrate that KRAS mutations seem not to correlate with the prognosis of patients with CRC.
Overall, these studies demonstrate that specific mutations in the type III repeat region of COMP do not affect its ability to form pentamers, suggesting that these mutations do not cause a dramatic conformational change of the protein that might leave unpaired cysteine residues.
Unlike with IHC biomarkers, where NSCLC subtype has largely been ignored, mutation studies have demonstrated prognostic effects for some mutations which are mostly found in lung adenocarcinomas.
